The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial

Abstract

IntroductionAs the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.MethodThis phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation, and recruited 20 patients. Oral Famotidine 160 mg four times a day was given to patients until the discharge day or for a maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.ResultsThe results showed a significant decrease in LDH (P = 0.01), mean WBC (P = 0.04) and length of stay (P = 0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P = 0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P = 0.02).ConclusionThis was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.

An Investigation of Anti-inflammatory Effects of Famotidine in Rats by Evaluating Inflammatory Cells and Lung Histopathology: An Airway Model

“…In this study, famotidine caused a reduction in the total WBC count in the BALF. This finding is consistent with a prior study that demonstrated a significant decrease in the WBC count for patients following treatment with famotidine when compared to placebo (Samimagham et al, 2021).…”

Adverse Effects of Gam-COVID-Vac (Sputnik V) Vaccine

“…Given the desperate need to develop vaccines as quickly as possible, much effort has been made to develop and manufacture vaccines to prevent the transmission of COVID-19 to healthy individuals (3)(4)(5). Numerous studies have focused on medication therapy and patient recovery; however, vaccination will significantly affect the mortality rate by reducing infection with COVID-19 (3)(4)(5)(6)(7)(8)(9). Nonetheless, like any other compound, vaccines can also cause local and systemic complications (4)(5)(6)(7)(8)(9)(10)(11)(12).…”

“…Numerous studies have focused on medication therapy and patient recovery; however, vaccination will significantly affect the mortality rate by reducing infection with COVID-19 (3)(4)(5)(6)(7)(8)(9). Nonetheless, like any other compound, vaccines can also cause local and systemic complications (4)(5)(6)(7)(8)(9)(10)(11)(12).…”